Aktuellt
SENASTE
Ahead of Q4, we look for clear sequential improvements and strong organic sales growth y/y. Backed by the recent regulatory clearance for SyMRI MSK in Europe, continued strong momentum for SyMRI as well as the expanded collaboration agreement with GE, we believe SyntheticMR remains well-positioned to reignite its growth trajectory ahead. We derive a DCF-based fair value range of SEK 269-356 (previously SEK 264-348) per share.
LÄS MER
